Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.32 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3920578 | 0.78 | RECQL (0.36) | KDM4EMEN1KMT2APOLBCYP2D6 | |
| SCHEMBL5259182 | 0.67 | — | — | |
| SCHEMBL5258503 | 0.67 | — | — | |
| SCHEMBL25398815 | 0.64 | CYP2D6 (0.33) | MEN1LMNAKMT2ANPSR1CYP2D6 | |
| SCHEMBL1828781 | 0.64 | — | — | |
| SCHEMBL8466516 | 0.64 | ESR1 (0.45) | KDM4EALDH1A1SMN1; SMN2CSNK2A2CSNK2B | |
| SCHEMBL7473806 | 0.64 | GAA (0.39) | SMN1; SMN2MEN1LMNAKMT2ACYP2D6 | |
| SCHEMBL1824933 | 0.61 | — | — | |
| SCHEMBL438321 | 0.61 | — | — | |
| SCHEMBL1669422 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140249165-A1 | PURINE DERIVATIVES FOR TREATMENT OF CYSTIC DISEASES | GENZYME CORPORATION (US) | 2014-09-04 | — | — | US | disclosed |
| US-6316456-B1 | Purine derivatives having, in particular, antiproliferative properties, and their biological uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2001-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249165-A1 | PURINE DERIVATIVES FOR TREATMENT OF CYSTIC DISEASES | TYMP, PKD1, CFTR | KDM4E 4153/4885ALDH1A1 1959/4885SMN1; SMN2 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.